Atorvastatin Calcium - CAS 134523-03-8
Catalog number: 134523-03-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
2(C33H34FN2O5).Ca
Molecular Weight:
1155.34
COA:
Inquire
Targets:
HMG-CoA Reductase (HMGCR)
Description:
Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol.
Purity:
>98%
Synonyms:
N/A
MSDS:
Inquire
InChIKey:
FQCKMBLVYCEXJB-MNSAWQCASA-L
InChI:
InChI=1S/2C33H35FN2O5.Ca/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);/q;;+2/p-2/t2*26-,27-;/m11./s1
Canonical SMILES:
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]
1.Oral Nanoparticulate Atorvastatin Calcium is More Efficient and Safe in Comparison to Lipicure in Treating Hyperlipidemia
A. K. Meena, D. Venkat Ratnam, G. Chandraiah. Lipids (2008) 43:231–241
We hypothesize that oral nanoparticulate formulations by virtue of their unique uptake mechanism and sustained release of the loaded drug would improve the efficacy of atorvastatin and at the same time reduce the associated side effects. Therefore, the present work deals with the development of atorvastatin calcium nanoparticles using a biodegradable polymer, poly(lactide-co-glycolate) (PLGA) and their evaluation in hyperlipidemic rats for efficiency as well as safety.
2.Rapid Insight into Heating-Induced Phase Transformations in the Solid State of the Calcium Salt of Atorvastatin Using Multivariate Data Analysis
Niels Peter Aae Christensen & Bernard Van Eerdenbrugh. Pharm Res (2013) 30:826–835
The aim of the present study was to investigate heatinginduced solid-state changes encountered during dehydration and melting of the trihydrate of the calcium salt of atorvastatin (THCaA, Fig. 2) with a focus on increasing the understanding of the physical instability of hydrate forming drugs at elevated temperatures in typical pharmaceutical manufacturing environments. The THCaA system is a prime candidate for the MCR approach on VT-XRPD data, because crystal structures have not so far been reported for any of the hydrate or anhydrous phases. Synchrotron XRPD data have previously been reported for THCaA, from which a unit cell has been deduced by Pawley refinement. However, full structural information has not been established. Here, we use MCR to decode the information in a variable-temperature XRPD data matrix and show that this approach can provide a rapid interpretation of complex dehydration behavior, even in the absence of detailed structural knowledge.
3.Synthesis, spectral, thermal, and antimicrobial studies of transition metal complexes of atorvastatin calcium as a lipid-lowering agent
Moamen S. Refat • Foziah A. Al-Saif. J Therm Anal Calorim (2015) 120:863–878
The thermal behavior of atorvastatin free ligand and their all complexes has been studied as a function of temperature. The decomposition nature of suggested structures with temperature and the residual products are given in Table 8. Thermal steps of atorvastatin complexes were discussed upon TG and DTG diagrams corresponding to these complexes are shown in Fig. 4.
4.Effects of atorvastatin on calciumregulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats
Lei Yao, Guo-Ping Chen, Xian Lu. Basic Res Cardiol 104:258–268 (2009)
The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No.85-23, revised 1996) and the guidelines of the Animal Care and Use Committee of Zhejiang University. Experiments were carried out using 8-week-old male SHR and Wistar Kyoto rats (WKY) (clean grade, provided by Shanghai Laboratory Animal Center, Chinese Academy of Sciences). Rats of each strain were divided into four groups, and were given (by gavage for 10 weeks) either 1 ml distilled water, atorvastatin (50 mg/kg/day), amlodipine (2 mg/kg/day), or both, mixed with 1 ml distilled water. In total, we used 8 groups of rats: WKY-placebo (n = 8), WKY-atorvastatin (n = 6), WKY-amlodipine (n = 4), WKY-combined (n = 4), SHR-placebo (n = 8), SHR-atorvastatin (n = 8), SHR-amlodipine (n = 5), and SHR-combined (n = 5). Amlodipine (2 mg/kg/day) was used as a drug control for blood pressure. All rats were housed under similar conditions on a 12-h light/dark cycle with the temperature maintained at 21 ± 1℃, humidity at 55% ± 5%, and free access to the same diet and water.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HMG-CoA Reductase (HMGCR) Products


CAS 93957-54-1 Fluvastatin

Fluvastatin
(CAS: 93957-54-1)

Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR) with IC50 of 8 nM. It belongs to a class of the statin drug and is ...

CAS 134523-03-8 Atorvastatin Calcium

Atorvastatin Calcium
(CAS: 134523-03-8)

Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol.

CAS 75330-75-5 Lovastatin

Lovastatin
(CAS: 75330-75-5)

Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).

CAS 73573-88-3 Mevastatin

Mevastatin
(CAS: 73573-88-3)

Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself.

CAS 93957-55-2 Fluvastatin Sodium

Fluvastatin Sodium
(CAS: 93957-55-2)

Fluvastatin Sodium inhibits HMG-CoA reductase activity with IC50 of 8 nM.

CAS 503-49-1 Meglutol

Meglutol
(CAS: 503-49-1)

Meglutol is a hypolipidemic agent which inhibits the activity of hydroxymethylglutarryl CoA reductases.

CAS 126411-39-0 SR 12813

SR 12813
(CAS: 126411-39-0)

SR 12813 is a pregnane X receptor (PXR) agonist (EC50 = 200 and 700 nM for human and rabbit PXR, respectively) that activates the farnesoid X receptor (FXR) at ...

CAS 81131-70-6 Pravastatin sodium

Pravastatin sodium
(CAS: 81131-70-6)

Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.

Chemical Structure

CAS 134523-03-8 Atorvastatin Calcium

Quick Inquiry

Verification code

Featured Items